KPV (Lysine-Proline-Valine — tripeptide fragment of alpha-MSH)
Anti-inflammatory tripeptide, the C-terminal fragment of α-MSH
At a glance
What it is: Anti-inflammatory tripeptide, the C-terminal fragment of α-MSH.
Primary research applications:
- Claimed: gut inflammation / IBD
- Claimed: skin conditions
Editorial summary: KPV is a small tripeptide with consistent anti-inflammatory effects in cell culture and rodent models of colitis. Human clinical data is very limited, and at least one translational trial (Lipotropin-1 / Zengen) in ulcerative colitis was discontinued.
What is KPV?
KPV is a three-amino-acid peptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). The tripeptide preserves much of α-MSH's anti-inflammatory activity while losing its effects on skin pigmentation.[1]
Mechanism of action
KPV appears to act intracellularly — entering cells via PepT1 and other transporters — to inhibit NF-κB activation and downstream pro-inflammatory cytokine production. This mechanism is most relevant in epithelial tissues including intestinal mucosa.
What the research shows
The peer-reviewed literature on KPV is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces gut inflammation in humans | Small clinical signal; program discontinued | Preliminary |
| Works as a 'BPC-157 alternative' for gut issues | Marketing framing; not compared head-to-head | Unsupported |
| Is well-tolerated | Yes in short-term animal and limited human data | Plausible |
Reported user experiences
How the research describes administration
In research settings, KPV has been administered orally, rectally (for colitis), and topically. No FDA-approved formulation.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
KPV has a coherent anti-inflammatory mechanism and decent preclinical data for gut indications, but human data is thin and its pharmaceutical development has not progressed. Marketing as a 'BPC-157 alternative' runs ahead of the evidence.
Frequently asked questions
Is KPV the same as alpha-MSH?
No. KPV is the C-terminal tripeptide of α-MSH — it retains much of the anti-inflammatory activity but not the skin-darkening effects.
Does KPV help ulcerative colitis?
Preclinical data and early human trials suggested a signal. The primary clinical program was discontinued. Current evidence in humans is limited.
Is KPV approved anywhere?
No. It is not FDA-approved for any indication.
References
- Dalmasso G, Charrier-Hisamuddin L, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. https://pubmed.ncbi.nlm.nih.gov/18061177/
- Wikberg JES, Muceniece R, Mandrika I, et al. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000;42:393-420. https://pubmed.ncbi.nlm.nih.gov/11023702/
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. https://pubmed.ncbi.nlm.nih.gov/18092346/